D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a high estimate of $18.00, and a low estimate of $18.00. No alteration is ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic competition to battles over getting more drugs to market.
Hosted on MSN1mon
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?VNDA is developing VGT-1849A, a novel antisense oligonucleotide (ASO)-based JAK2 inhibitor for treating PV and other JAK2-driven hematologic malignancies. VNDA's Zacks Rank & Rising Estimates ...
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...
Shares of NASDAQ VNDA opened at $4.41 on Monday. The stock has a market capitalization of $257.15 million, a PE ratio of -15.75 and a beta of 0.77. Vanda Pharmaceuticals has a 12-month low of $3. ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback